Protein kinase c iota

Abstract

The invention involves PKC ι signaling. The invention provides, for example, transgenic animals, inhibitors of PKC ι signaling, methods for inhibiting PKC ι signaling, methods for identifying inhibitors of PKC ι signaling, and methods for diagnosing cancer.

1 . A method for inhibiting a protein kinase C iota polypeptide response in a mammal, said method comprising administering an inhibitor to said mammal under conditions wherein said response is inhibited, wherein said inhibitor reduces the interaction between a protein kinase C iota polypeptide and a polypeptide selected from the group consisting of Par-6, Src, Par-4, p62/ZIP, and Par-3 polypeptides. 
     
     
         2 . The method of  claim 1 , wherein said response is cell transformation, development of cancer, or colon carcinogenesis. 
     
     
         3 . The method of  claim 1 , wherein said inhibitor is a polypeptide fragment. 
     
     
         4 . The method of  claim 3 , wherein said polypeptide fragment comprises an amino acid sequence present in said protein kinase C iota polypeptide. 
     
     
         5 . The method of  claim 1 , wherein said inhibitor is aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, or hexestrol.